SIREN : 789692332
MEDIPPEX is a French company founded 13 years ago, specialized in the sector Fabrication d'emballages en matières plastiques. Based in GRENOBLE (38000), this company of category PME shows in 2024 a revenue of 7.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 755 858 € | 7 879 016 € | 6 933 040 € | 7 085 798 € | 7 465 521 € | 7 291 486 € | 7 330 103 € | 7 032 291 € | 5 856 890 € |
| Net income | -684 823 € | -616 739 € | -718 750 € | 21 861 € | 346 173 € | 127 105 € | 164 541 € | 52 191 € | -95 905 € |
| EBITDA | -764 080 € | -184 087 € | -324 190 € | -371 504 € | 180 571 € | 203 982 € | 200 200 € | 133 687 € | -112 653 € |
| Net margin | -8.8% | -7.8% | -10.4% | 0.3% | 4.6% | 1.7% | 2.2% | 0.7% | -1.6% |
In 2024, MEDIPPEX achieves revenue of 7.8 M€. Revenue is growing positively over 9 years (CAGR: +3.6%). Slight decline of -2% vs 2023. After deducting consumption (3.4 M€), gross margin stands at 4.4 M€, i.e. a rate of 57%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -764 k€, representing -9.9% of revenue. Warning negative scissor effect: despite revenue change (-2%), EBITDA varies by -315%, reducing margin by 7.5 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -685 k€ (-8.8% of revenue), which will impact equity.
7 755 858 €
4 385 413 €
-764 080 €
-1 252 230 €
-684 823 €
-9.9%
The debt ratio (= Financial debt / Equity x 100) stands at -5112%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -1%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
-5112.213%
-1.298%
-7.96%
-5.272
47.0%
In 2024, the debt ratio of MEDIPPEX (-5112.21) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of MEDIPPEX (-1.3%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2024, the repayment capacity of MEDIPPEX (-5.27) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 143.20. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
143.201
-6.127
In 2024, the liquidity ratio of MEDIPPEX (143.20) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of MEDIPPEX (-6.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 16 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 35 days. Favorable situation: supplier credit is longer than customer credit by 19 days. Inventory turnover is 63 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 49 days of revenue, i.e. 1.1 M€ to permanently finance.
1 051 539 €
16 j
35 j
63 j
49 j
Based on 76 transactions of similar company sales
(all years),
the value of MEDIPPEX is estimated at
1 577 906 €
(range 754 316€ - 2 123 473€).
The price/revenue ratio is 0.20x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 76 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDIPPEX with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication d'emballages en matières plastiques
The revenue of MEDIPPEX in 2024 is 7.8 M€.
MEDIPPEX recorded a net loss in 2024.
The headquarters of MEDIPPEX is located in GRENOBLE (38000), in the department Isere.
The tax return of MEDIPPEX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDIPPEX operates in the sector Fabrication d'emballages en matières plastiques (NAF code 22.22Z). See the 'Sector positioning' section above to compare the company with its competitors.